Radius Health (RDUS) : The value of composite uptick trades was $0.9 million, whereas, the value of composite downtick trades was $1.92 million. The uptick to downtick ratio stood at 0.47 with a negative money flow of ($1.02) Million during Fridays trading session. The block trades money flow was negative ($0.72 million). The transaction of the trades on downticks amounted to $0.72 million, which confirms investors selling on the strength of price. Radius Health (RDUS) gained 84 cents at $56.52, an increase of 1.51% over the previous days close.
The company Insiders own 16.8% of Radius Health shares according to the proxy statements.
Radius Health (NASDAQ:RDUS): The stock opened at $56.26 and touched an intraday high of $57.71 on Friday. During the day, the stock corrected to an intraday low of $55.6, however, the bulls stepped in and pushed the price higher to close in the green at $56.56 with a gain of 1.58% for the day. The total traded volume for the day was 897,120. The stock had closed at $55.68 in the previous trading session.
Radius Health (RDUS) : Traders are bullish on Radius Health (RDUS) as it has outperformed the S&P 500 by a wide margin of 3.03% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.66%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 4.18% in the last 1 week, and is up 2.89% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.